Professor Jack Cuzick

CBE, PhD, FRS, FMedSci, FRCP (hon)
John Snow Professor of Epidemiology
Research Theme Lead
Research Focus

I am John Snow Professor of Epidemiology at Queen Mary University of London. My current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening.

Key Publications

Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol (2015) 16(1):67-75. PMID: 25497694

Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet (2014) 383(9922):1041-8. PMID: 24333009

Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Onc (2011) 12(3):245-255. PMID: 21310658

A breast cancer prediction model incorporating familial and personal risk factors. Statist Med (2004) 23: 1111-1130. PMID: 15057881

Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet (2003) 362: 1871-1876. PMID: 14667741

Major Funding
  • 2018-2023- CRUK, Catalyst
  • 2017-2020- Barts Charity, Preventative Neurology
  • 2014-2019- CRUK, Cancer Prevention
  • 2007-2019- CRUK, IBIS II
Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Research

I am currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. I have worked extensively in breast cancer and was the first to report the effect of tamoxifen on contralateral tumours as an indicator of its potential chemopreventive role. I demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness.

I am involved in studies on the use of HPV assays for cervical screening, the use of flexible sigmoidoscopy for colorectal cancer screening and markers for the behaviour of early prostate cancer.

I am the statistician for several major breast cancer trials and maintain an active interest in developing new statistical methodology, especially in the area of adjustments for non-compliance and cross-over, and multi-arm clinical trials.

Other Activities
  • Fellow of the Academy of Medical Sciences
  • Fellow of the Royal Society
  • Science Strategy Committee member for Breast Cancer Now
  • Research Strategy Group member for Prostate Cancer UK
Major Funding
  • 2018-2023- CRUK, Catalyst
  • 2017-2020- Barts Charity, Preventative Neurology
  • 2014-2019- CRUK, Cancer Prevention
  • 2007-2019- CRUK, IBIS II
Recent Publications

The importance of long-term follow up of participants in clinical trials. Cuzick J Br J Cancer (2022) (2)
https://www.ncbi.nlm.nih.gov/pubmed/36456713

Interpreting the results of noninferiority trials—a review Cuzick J, Sasieni P British Journal of Cancer (2022) 127(7) 1755-1759

DNA methylation testing with S5 for triage of high-risk HPV positive women Adcock R, Nedjai B, Lorincz AT et al. International Journal of Cancer (2022) 151(7) 993-1004

Validation of the cell cycle progression score to differentiate indolent from aggressive prostate cancer in men diagnosed through transurethral resection of the prostate biopsy Cuzick JM, Stone S, Lenz L et al. Cancer Reports (2022) 5(7)

Breast cancer risk stratification in women of screening age: Incremental effects of adding mammographic density, polygenic risk, and a gene panel Evans DGR, van Veen EM, Harkness EF et al. Genetics in Medicine (2022) 24(7) 1485-1494

Adherence to National Guidelines on Cervical Screening: A Population-Based Evaluation From a Statewide Registry Castle PE, Kinney WK, Chen L et al. Journal of the National Cancer Institute (2022) 114(7) 626-630

Assessment of Risk Factors and Early Presentations of Parkinson Disease in Primary Care in a Diverse UK Population Simonet C, Bestwick J, Jitlal M et al. JAMA Neurology (2022) 79(7) 359-369

The Lancet Breast Cancer Commission: tackling a global health, gender, and equity challenge Coles CE, Anderson BO, Cameron D et al. The Lancet (2022) 399(7) 1101-1103

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials Bradley R, Braybrooke J, Gray R et al. The Lancet Oncology (2022) 23(7) 382-392

Comparison of StemPrintER with Oncotype DX Recurrence Score for predicting risk of breast cancer distant recurrence after endocrine therapy Pece S, Sestak I, Montani F et al. European Journal of Cancer (2022) 164(7) 52-61

For additional publications, please click here
Biography

I received my BSc in Mathematics and Physics from Harvey Mudd College, Claremont, California. I then studied an MSc in Mathematics at the University of London. I obtained my PhD in Mathematics from Claremont Graduate School, Claremont, California.

I was appointed John Snow Professor of Epidemiology at Queen Mary University of London. In 2017, I was awarded a CRUK Lifetime Achievement Award and a CBE.